PURPOSE: Relapsed high-risk neuroblastoma patients still have a poor prognosis. This phase-II trial assessed a new topotecan containing chemotherapy approach in patients with active disease. METHODS: Chemotherapy consisted of topotecan (1.0 mg/m(2)/day 168-h continuous infusion), cyclophosphamide (100 mg/m(2)/day 1-h-infusion days 1-7 starting 6 h prior to topotecan), and etoposide (100 mg/m(2)/day 1-h-infusion days 8-10). Patients with relapsed neuroblastoma were scheduled for six cycles, untreated patients for two cycles followed by standard high-risk treatment. RESULTS:Main toxicity observed during 153 cycles were grade 3-4 leukopenia (97% of cycles), thrombocytopenia (92%), neutropenic fever (52%), and mucositis (10%). No treatment related fatal toxicity occurred. Complete or partial response was achieved in 19 of 31 (61%) evaluable relapsed patients and 8 of 11 (72%) untreated patients. CONCLUSIONS: The combination of topotecan, cyclophosphamide, and etoposide is tolerable and effective in relapsed and untreated neuroblastoma. Myelotoxicity is the main side effect but seems justified in view of the encouraging response rates. A randomized phase-III trial in primary disease has been commenced.
RCT Entities:
PURPOSE: Relapsed high-risk neuroblastomapatients still have a poor prognosis. This phase-II trial assessed a new topotecan containing chemotherapy approach in patients with active disease. METHODS: Chemotherapy consisted of topotecan (1.0 mg/m(2)/day 168-h continuous infusion), cyclophosphamide (100 mg/m(2)/day 1-h-infusion days 1-7 starting 6 h prior to topotecan), and etoposide (100 mg/m(2)/day 1-h-infusion days 8-10). Patients with relapsed neuroblastoma were scheduled for six cycles, untreated patients for two cycles followed by standard high-risk treatment. RESULTS: Main toxicity observed during 153 cycles were grade 3-4 leukopenia (97% of cycles), thrombocytopenia (92%), neutropenic fever (52%), and mucositis (10%). No treatment related fatal toxicity occurred. Complete or partial response was achieved in 19 of 31 (61%) evaluable relapsed patients and 8 of 11 (72%) untreated patients. CONCLUSIONS: The combination of topotecan, cyclophosphamide, and etoposide is tolerable and effective in relapsed and untreated neuroblastoma. Myelotoxicity is the main side effect but seems justified in view of the encouraging response rates. A randomized phase-III trial in primary disease has been commenced.
Authors: A Dowlati; N Levitan; N H Gordon; C L Hoppel; D M Gosky; S C Remick; S T Ingalls; S J Berger; N A Berger Journal: Cancer Chemother Pharmacol Date: 2001 Impact factor: 3.333
Authors: G Vassal; C Pondarré; C Cappelli; M J Terrier-Lacombe; I Boland; J Morizet; J Bénard; A M Vénuat; P Ardouin; O Hartmann; A Gouyette Journal: Eur J Cancer Date: 1997-10 Impact factor: 9.162
Authors: Carlos Rodríguez-Galindo; Najat C Daw; Sue C Kaste; William H Meyer; Jeffrey S Dome; Alberto S Pappo; Bhaskar N Rao; Charles B Pratt Journal: J Pediatr Hematol Oncol Date: 2002-05 Impact factor: 1.289
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: M Krumbholz; J Bradtke; D Stachel; O Peters; B Hero; W Holter; R Slany; M Metzler Journal: Bone Marrow Transplant Date: 2015-07-06 Impact factor: 5.483
Authors: Rajen Mody; Arlene Naranjo; Collin Van Ryn; Alice L Yu; Wendy B London; Barry L Shulkin; Marguerite T Parisi; Sabah-E-Noor Servaes; Mitchell B Diccianni; Paul M Sondel; Julia G Bender; John M Maris; Julie R Park; Rochelle Bagatell Journal: Lancet Oncol Date: 2017-05-23 Impact factor: 41.316
Authors: Hernan Carol; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; John M Maris; Stephen T Keir; Amy Watkins; Malcolm A Smith; Richard B Lock Journal: Pediatr Blood Cancer Date: 2010-05 Impact factor: 3.167
Authors: Tasnim Ara; Liping Song; Hiroyuki Shimada; Nino Keshelava; Heidi V Russell; Leonid S Metelitsa; Susan G Groshen; Robert C Seeger; Yves A DeClerck Journal: Cancer Res Date: 2009-01-01 Impact factor: 12.701
Authors: Tasnim Ara; Rie Nakata; Michael A Sheard; Hiroyuki Shimada; Ralf Buettner; Susan G Groshen; Lingyun Ji; Hua Yu; Richard Jove; Robert C Seeger; Yves A DeClerck Journal: Cancer Res Date: 2013-04-30 Impact factor: 12.701
Authors: Brian H Kushner; Shakeel Modak; Kim Kramer; Michael P LaQuaglia; Karima Yataghene; Ellen M Basu; Stephen S Roberts; Nai-Kong V Cheung Journal: Cancer Date: 2014-04-01 Impact factor: 6.860
Authors: Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang Journal: Med Res Rev Date: 2020-11-06 Impact factor: 12.944